Election of Class III Director to serve until the Companys 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Milind Deshpande, Ph.D.
Election of Class III Director to serve until the Companys 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Kathleen Tregoning
To ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2026.
To approve by an advisory vote the compensation of the Companys named executive officers, as disclosed in the proxy statement.
To approve an amendment to the Companys Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares.
To approve adoption of the 2026 Spero Therapeutics, Inc. Stock Incentive Plan.